In 2018, podocalyxin (PODXL), a cell surface protein whose expression is upregulated during EMT, was found to be essential for mediating the extravasation process of human breast cancer cells by interacting with actin cytoskeletal linker protein ezrin, thereby causing cytoskeletal rearrangements that promote the transition of the cancer cell into a shape that is optimal for extravasation [35]. The gene discussed is PODXL; the disease is breast cancer.